Dr. Silver on Hydroxyurea and Interferon in MPNs

Video

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use hydroxyurea and interferons in myeloproliferative neoplasms.

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use hydroxyurea and interferons in myeloproliferative neoplasms (MPNs).

The most commonly used drug in MPNs, Silver says, is hydroxyurea. There is no biologic basis for its use as it just kills cells indiscriminately. In addition, hydroxyurea is taken orally and presents significant side effects including nausea and vomiting.

The new use of interferon was shaped by the fact that doses were previously too high: side effects were too great and the agent was never promoted. Interferon has shown efficacy in chronic hepatitis with lower doses, causing a renewed interest in the hematologic space.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD